Despite advances in gene therapy, delivery of therapeutic material to a specific tissue remains a challenge. This proposal tackles the long-standing delivery issue in the gene therapy field by engineering novel vehicles for muscle tissue. Our approach to this challenge is to harness the activities of the proteins that directly control myoblast fusion, a process essential for multinucleated skeletal muscle fibers to develop, repair, and regenerate. Fusion of a myoblast membrane with a myofiber membrane allows entry of the progenitor into the syncytium, which is a process that, if understood molecularly and properly engineered, could empower delivery vehicles to transduce muscle. We will leverage our discoveries of Myomaker and Myomerger, which represent the minimal and essential machinery for myoblast fusion, to engineer enveloped viruses and exosomes into specific and efficient vehicles that deliver therapeutic material to muscle cells. Evidence for the challenges associated with muscle gene therapy is the lack of a treatment for genetic muscle diseases such as muscular dystrophy. Adeno-associated virus (AAV) is the current standard for efficacious skeletal muscle gene therapy, but the field has had to reconcile an apparent inability to target muscle stem cells, a goal that would likely need to be achieved for sustained corrective outcomes. The principal rationale of this proposal is that with the discovery of muscle-specific fusogens, it is time to re-examine the potential of non-AAV vectors such as lentiviral vectors and non-viral particles (exosomes) as delivery vehicles that could be used with AAV or independently. Because Myomaker and Myomerger function at the cell surface of myoblasts to drive the membrane remodeling processes necessary for fusion, we propose that their presence on viral envelopes and exosomes will increase entry into muscle. In the R61 phase of this project, we will engineer and optimize Myomaker and Myomerger, or regions of these proteins, on the envelope of viruses and the surface of exosomes. We will also assess and optimize the ability of these engineered vehicles to drive entry into muscle and non-muscle tissues in vitro and in vivo. In the R33 phase, we will validate the use of the delivery vehicles optimized in the R61 phase to test their ability to deliver clinically relevant levels of therapeutic material. Specifically, we will determine if our optimized delivery vehicles can restore dystrophin and improve muscle function in the dystrophin-deficient mdx mouse model. Overall, this work promises to open up a new area of investigation into regenerative medicine by innovating novel delivery vehicles that could be utilized for a myriad of musculoskeletal conditions.
The goal of this project is to develop new technologies to deliver therapeutic material to muscle. The delivery vehicles engineered using the muscle fusogens could be applied to augment a wide-range of musculoskeletal conditions. !
